Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rang in Aktien #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Aktienkurs
$137.21
Marktkapitalisierung
$170.34B
Veränderung (1 Tag)
-2.76%
Veränderung (1 Jahr)
28.14%
Land
US
Handel Gilead Sciences, Inc. (GILD)

Kategorie

P/S-Verhältnis für Gilead Sciences, Inc. (GILD)
P/S-Verhältnis zum March 2026 TTM: 6.11
Laut den neuesten Finanzberichten und dem Aktienkurs von Gilead Sciences, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 6.11. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 4.01.
P/S-Verlauf für Gilead Sciences, Inc. von 2000 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 6.11 17.79%
2025 5.19 29.46%
2024 4.01 7.44%
2023 3.73 -5.59%
2022 3.95 18.24%
2021 3.34 12.60%
2020 2.97 -19.31%
2019 3.68 0.19%
2018 3.67 2.31%
2017 3.59 13.67%
2016 3.16 -30.48%
2015 4.54 -21.25%
2014 5.76 -43.76%
2013 10.25 78.72%
2012 5.73 51.64%
2011 3.78 -3.10%
2010 3.90 -30.11%
2009 5.58 -36.72%
2008 8.82 -12.66%
2007 10.10 2.59%
2006 9.85 -16.34%
2005 11.77 3.14%
2004 11.41 -15.54%
2003 13.51 -5.12%
2002 14.24 -46.77%
2001 26.76 38.69%
2000 19.29 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
14.26 133.21%
US
4.96 -18.85%
GB
6.18 1.07%
US
6.35 3.89%
US
5.18 -15.33%
CH